Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 11Cyclophosphamide 8Gemcitabine 7Cisplatin 7tislelizumab 5Docetaxel 5Nivolumab 4Injections 4spartalizumab 3regorafenib 3Trastuzumab 3Oncolytic Virotherapy 3Irinotecan 3Filgrastim 3Drug Therapy 3Doxorubicin 3Carboplatin 3Bortezomib 3tazemetostat 2pazopanib 2liposomal doxorubicin 2ganitumab 2conatumumab 2belinostat 2Temozolomide 2Taxes 2Tamoxifen 2Sorafenib 2Riluzole 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × OSI 930 × Thoracic × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡